SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (235)1/29/1997 1:09:00 PM
From: Peter Church   of 6136
 
Do you know when the FDA advisory committee meets? Is there any indication of the timing of FDA approval?

I have heard talk that some of the Treat Early, Treat Hard camp of researchers who attended the Washington conference prefer Viracept as a 1st treatment PI for new cases. Is that because it is the most easily tolerated or because of its resistance pattern? Maybe the decision is subjective and a matter of patient preference. I wonder if you heard about any data on that issue.

Thanks for your very insightful commentary.

---Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News